A Problem of Sarcoidosis Treatment: Cause for Discussion and Controlled Trials | CMAC

A Problem of Sarcoidosis Treatment: Cause for Discussion and Controlled Trials

Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6(3):232-242

​ Vizel A.A., Gouryleva M.E., Vizel E.A.
sarcoidosis pathogenesis treatment corticosteroids
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6(3):232-242

Abstract

This literature review presents approaches to the treatment of sarcoidosis, which are based on currently offered hypothesis of its pathogensis.These include: influence on granulomatous inflammation (corticosteroids, cytotoxic agents, anti-malaria drugs, non-steroidal anti-inflammatory drugs); influence on secondary immune deficiency; fight with oxidative stress; influence on antigenic triggers; normalizing diet and mode of living; lowering iatrogenic effects.Authors point out that physicians should use an thorough approach, taking into account effect of pharmacotherapy on natural course of the disease and possibility of adverse drug reactions, when choosing model of management of the patients with sarcoidosis (treatment or close monitoring).The unconventional and alternative methods of treatment of sarcoidosis are also considered in this review; however, these methods need further controlled clinical trials to establish their efficacy and safety.Authors propose an integrated system of management of the patients with sarcoidosis.

  • 1. Sones M., Israel H.L., Dratman M.B., Frank J.H. Effect of cortisone in sarcoidosis. N Engl J Med 1951; 244:209-13.
  • 2. Paramothayan S., Jones P.W. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002; 287:1301-7.
  • 3. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J 1999; 14:735-7.
  • 4. Хоменко А.Г., Ерохин В.В., Филиппов В.П. и др. Саркоидоз как системный гранулематоз. М.: Медицина; 1999. 39 с.
  • 5. Борисов С.Е., Соловьева И.П., Ефимьевский В.П. и др. Диагностика и лечение саркоидоза органов дыхания. Пособие для фтизиатров и пульмонологов. Проблемы туберкулеза 2003; (6):51-64.
  • 6. Rizzato G., Montemurro L., Colombo P. The late followup of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15:52-8.
  • 7. Добош К.В. Определение эффективности ингаляционных кортикостероидов, на примере ингакорта, в лечении больных саркоидозом легких. Автореф. дис. канд. мед. наук. Санкт-Петербург; 1999.
  • 8. Дауров Б.И. Проблемы реактивации саркоидоза: причины и возможные пути ее решения. Пульмонология 2002. Приложение. 12-й Национальный конгресс по болезням органов дыхания: сборник резюме. Резюме № 255.
  • 9. Judson M.A. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 1999; 115:1158-65.
  • 10. Бурухина Л.В., Светлаков Б.И., Порсева Л.П. и др. Особенности клиники и течения саркоидоза в условиях Западного Урала. Проблемы туберкулеза 2002; (11): 37-40.
  • 11. Baughman R.P., Sharma O.P., Lynch J.P. 3rd. Sarcoidosis: is therapy effective? Semin Respir Infect 1998; 13:255–73.
  • 12. James D.G. Sarcoidosis. Curr Med Drugs 1967; 7(9):10-21.
  • 13. Fanburg B.L. Drug therapy reviews: treatment of sarcoidosis. Am J Hosp Pharm 1979; 36:351-4.
  • 14. Хоменко А.Г., Озерова Л.В., Романов В.В. и др. Саркоидоз: 25-летний опыт клинического наблюдения. Проблемы туберкулеза 1996; (6):64-8.
  • 15. Reich J.M. Adverse long-term effect of corticosteroid therapy in recent-onset sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:227-34.
  • 16. Илькович М.М., Добош К.В., Перлей В.Е. и др. Комплексная оценка эффективности различных способов кортикостероидной терапии в лечении саркоидоза лёгких. Пульмонология 1999; (3):71-5.
  • 17. Milman N. Oral and inhaled corticosteroids in the treatment of pulmonary sarcoidosis: A critical reappraisal. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15:150-7.
  • 18. Lower E.E., Baughman R.P. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 1990; 299:153-7.
  • 19. Shetty A.K., Gedalia A. Sarcoidosis: a pediatric perspective. Clin Pediatr (Phila) 1998; 37:707-17.
  • 20. Fazzi P. Pharmacotherapeutic management of pulmonary sarcoidosis. Am J Respir Med 2003; 2:311-20.
  • 21. Kang S., Suh J.H. Radiation therapy for neurosarcoidosis: report of three cases from a single institution. Radiat Oncol Investig 1999; 7:309-12.
  • 22. Baltzan M., Mehta S., Kirkham T.H., Cosio M.G. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999; 160:192-7.
  • 23. Belfer M.H., Stevens R.W. Sarcoidosis: a primary care review. Am Fam Physician 1998; 58:2041-50, 2055-6.
  • 24. Ziegenhagen M.W., Fitschen J., Martinet N., et al. Serum level of soluble tumour necrosis factor receptor II (75 kDa) indicates inflammatory activity of sarcoidosis. J Intern Med 2000; 248:33-41.
  • 25. Baughman R.P., Lynch J.P. Difficult treatment issues in sarcoidosis. J Intern Med 2003; 253:41-5.
  • 26. Baughman R.P. Therapeutic options for sarcoidosis: new and old. Curr Opin Pulm Med 2002; 8:464-9.
  • 27. Nguyen Y.T., Dupuy A., Cordoliani F., et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 2004; 50:235-41.
  • 28. Walter M.C., Lochmuller H., Schlotter-Weigel B., et al. Successful treatment of muscle sarcoidosis with thalidomide. Acta Myol 2003; 22:22-5.
  • 29. Tong Z.H., Dai H.P., Chen B.M., et al. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline. Zhonghua Jie He He Hu Xi Za Zhi 2003; 26 (7):5-8.
  • 30. Nasretdinova G.R., Vizel A.A., Gouryleva M.E., Amirov N.B. Pentoxifylline in treatment of pulmonary sarcoidosis. Eur Resp J 2002; 20(Suppl 38):433s.
  • 31. Utz J.P., Limper A.H., Kalra S., et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124:177-85.
  • 32. Khanna D., Liebling M.R., Louie J.S. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003; 30:1864-7.
  • 33. Sharma O.P. Hypercalcemia in granulomatous disorders: a clinical review. Curr Opin Pulm Med 2000; 6:442-7.
  • 34. Озерова Л.В. Саркоидоз: диагностика, клиника, течение и лечение. Проблемы туберкулеза 1995; (4):51-4.
  • 35. Романов В.В. Экстракорпоральные методы в лечении больных саркоидозом. Проблемы туберкулеза 2001; (3):45-9.
  • 36. Wilton J.M. Levamisole in chronic inflammatory diseases. J Rheumatol 1978; 4(Suppl):101-13.
  • 37. Шаповалова Т.В., Дорошенкова А.Е., Сигидина А.Н. Иммунокоррекция в лечении саркоидоза. Пульмонология 1995. 5-й Национальный конгресс по болезням органов дыхания: сборник резюме. Резюме № 273.
  • 38. Костина З.И., Браженко Н.А., Герасимова Е.В. и др. Клинико-иммунологическая характеристика и особенности лечения больных с рецидивирующими формами саркоидоза органов дыхания. Проблемы туберкулеза 2001; (3):37-42.
  • 39. Кеворков Н.Н., Горовиц Г.А., Бахметьев С.А. Ликопид в комплексном иммунокорригирующем лечении больных саркоидозом лёгких и внутригрудных лимфатических узлов. Терархив 2002; (3):55-8.
  • 40. Зубович Г.Л., Абрамовская А.К., Камышников В.С. и др. Показатели гомеостаза у больных саркоидозом органов дыхания. Пульмонология 1996; (2):50-4.
  • 41. Rothkrantz-Kos S., Drent M., Vuil H., et al. Decreased redox state in red blood cells from patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:114-20.
  • 42. Du Bois R.M., Goh N., McGrath D., Cullinan P. Is there a role for microorganisms in the pathogenesis of sarcoidosis? J Intern Med 2003; 253:4-17.
  • 43. Burnet F.M. The clonal selection theory of acquired immunity. Cambridge: Cambridge University Press; 1959.
  • 44. Mankiewicz E., van Walbeek R. Mycobacteriophages: their role in tuberculosis and sarcoidosis. Arch Environ Health 1962; 5:122-8.
  • 45. Cantwell A.R. Jr. Histologic observations of variably acid-fast pleomorphic bacteria in systemic sarcoidosis: a report of 3 cases. Growth 1982; 46:113-25.
  • 46. Almenoff P.L., Johnson A., Lesser M., Mattman L.H. Growth of acid fast L-forms from the blood of patients with sarcoidosis. Thorax 1996; 51:530-3.
  • 47. Graham D.Y., Markesich D.C., Kalter D.C. Isolation of cell wall-deficient acid fast bacteria from skin lesions in patients with sarcoidosis. In: Grassi C., Rizzato G., Pozzi E., editors. Sarcoidosis and other granulomatous disorders. Amsterdam: Elsevier; 1998. p. 161–4.
  • 48. Barth C.L., Judge M.S., Mattman L.H., Hessburg P.C. Isolation of an acid-fast organism from the aqueous humour in a case of sarcoidosis. Henry Ford Hosp Med J 1979; 27:127-33.
  • 49. Wilsher M.L., Menzies R.E., Croxson M.C. Mycobacterium tuberculosis DNA in tissues affected by sarcoidosis. Thorax 1998; 53:871-4.
  • 50. Озерова Л.В., Романов В.В., Рыбакова Н.П. и др. Излечение саркоидоза по данным диспансерного наблюдения 1992-1999 гг. Пульмонология 1999; (3):57-61.
  • 51. Puscinska E., Goljan A., Zych D., et al. Evaluation of effects of antituberculous treatment on the course of sarcoidosis. Pneumonol Alergol Pol 1996; 64:261-6.
  • 52. Hernandez-Cruz B., Ponce-de-Leon-Rosales S., Sifuentes-Osornio J., et al. Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases: A case-control study. Clin Exp Rheumatol 1999; 17:81-7.
  • 53. Борисов С.Е., Купавцева Е.А. Лечение саркоидоза. Сборник научных трудов, посвящённый 80-летию института. М.: НИИ фтизиопульмонологии ММА им. И.М. Сеченова; 1998. с. 62-8.
  • 54. Drent M., Jacobs J.A., de Vries J., et al. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J 1999; 13:1338-44.
  • 55. Jacob F. Could Borrelia burgdorferi be a causal agent of sarcoidosis? Med Hypotheses 1989; 30:241-3.
  • 56. Ishige I., Usui Y., Takemura T., Eishi Y. Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet 1999; 354:120-3.
  • 57. Gazouli M., Ikonomopoulos J., Trigidou R., et al. Assessment of mycobacterial, propionibacterial, and human herpesvirus 8 DNA in tissues of greek patients with sarcoidosis. J Clin Microbiol 2002; 40:3060-3.
  • 58. Nilsson K., Pahlson C., Lukinius A., et al. Presence of Rickettsia helvetica in granulomatous tissue from patients with sarcoidosis. J Infect Dis 2002; 185:1128-38.
  • 59. Puolakkainen M., Campbell L.A., Kuo C.C., et al. Serological response to Chlamydia pneumoniae in patients with sarcoidosis. J Infect 1996; 33:199-205.
  • 60. Nunes H., Deny P., Raphael M., Valeyre D. Chronic infiltrative lung disease and viruses. Rev Mal Respir 2001; 18:247-55.
  • 61. Mitchell D.N. The nature and physical characteristics of a transmissible agent from human sarcoid tissue. Ann N Y Acad Sci 1976; 278:233-48.
  • 62. Schmidt R.J., Bender F.H., Chang W.W., Teba L. Sarcoidosis after renal transplantation. Transplantation 1999; 68:1420–3.
  • 63. Hunt J., Gordon F.D., Jenkins R.L., et al. Sarcoidosis with selective involvement of a second liver allograft: report of a case and review of the literature. Mod Pathol 1999; 12:325-8.
  • 64. Heyll A., Meckenstock G., Aul C., et al. Possible transmission of sarcoidosis via allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14:161-4.
  • 65. Padilla M.L., Schilero G.J., Teirstein A.S. Donoracquired sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:18-24.
  • 66. Walker S., Mikhail G., Banner N., et al. Medium term results of lung transplantation for end stage pulmonary sarcoidosis. Thorax 1998; 53:281-4.
  • 67. Bachelez H., Senet P., Cadranel J., et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001; 137:69-73.
  • 68. Marshall T.G., Marshall F.E. Antibiotics in sarcoidosis – reflections on the first year. JOIMR 2003; 1(3):2.
  • 69. Frangova Youroukova V., Ivanov St., Popov G. Chlamydia pneumoniae and respiratory tract diseases in Bulgaria. Eur Resp J 1997; 10(Suppl 25):322-23s.
  • 70. Rybojad M. Management of severe skin disorders in sarcoidosis. Ann Med Interne (Paris) 2001; 152: 89-95.
  • 71. Anastasatu C., Albu A., Burnea D., et al. The advantages of Reprimun therapy in pulmonary sarcoidosis and other granulomatous diseases. Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol 1989; 38:259-64.
  • 72. Toutous-Trellu L., Ninet B., Rohner P., et al. Three cases of cutaneous sarcoidosis: search for bacterial agent by the 16S RNA gene analysis and treatment with antibiotics. Dermatol 2000; 200:342-5.
  • 73. Валиев Р.Ш., Филатова М.С. Психосоматические соотношения при саркоидозе. Проблемы туберкулеза 1999; (4):10-1.
  • 74. Escande M., Gardes J.P., Gayral L.F. Reactions and psychic disorders in Besnier-Boeck-Schaumann disease: Clinical and psychological approach; application of a scale of aggressive behavior to the mental profile. Ann Med Psychol (Paris) 1980; 138:813-28.
  • 75. Güneylioglu D., Özseker F., Baran A., et al. Sarcoidosis and depression. Eur Resp J 2002; 20(Suppl 38):435s.
  • 76. Гурылева М.Э., Визель Е.А., Казаков И.М. и др. Саркоидоз глазами пациента: результаты опросов больных. Проблемы туберкулеза 2003; (6):10-3.
  • 77. Nader T., Rothenberg S., Averbach R., et al. Improvements in chronic diseases with a comprehensive natural medicine approach: a review and case series. Behav Med 2000; 26:34-46.
  • 78. Селивонина Ж.Э., Катрушенков А.В., Сурженко И.О., Дементьева М.П. Динамика лёгочного кровотока у больных саркоидозом лёгких под влиянием разгрузочно-диетической терапии. Пульмонология 1995. Приложение. 5-й Национальный конгресс по болезням органов дыхания: сборник резюме. Резюме № 268.
  • 79. Cogrel O., Doutre M.S., Marliere V., et al. Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases. Br J Dermatol 2002; 146:320-4.
  • 80. Vergne P., Bertin P., Bonnet C., et al. Drug-induced rheumatic disorders: incidence, prevention and management. Drug Saf 2000; 23:279-93.
  • 81. Шмелев Е.И. Дифференциальная диагностика интерстициальных болезней лёгких. Consilium medicum 2003; 5:176-81.
  • 82. Визель А.А., Булашова О.В., Амиров Н.Б. и др. Интегральная модель диагностики и наблюдения больных саркоидозом в современных условиях. Пульмонология 2003; (3):74-9.
  • 83. Drent M. Sarcoidosis: benefits of a multidisciplinary approach. Eur J Intern Med 2003; 14:217-20.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared